Browse Studies — Arctuva

Phase 1

A Phase 1 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO 006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in se…

Head & Neck Squamous Cell CarcinomaNon-Small Cell Lung CancerEsophageal Cancer+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.